Dr Andrew Ford
Started at UWA: 2009
Dementia Research Development Fellow, 2016-2019
Awarded the Advanced Trainee Project Prize Royal Australian and New Zealand College of Psychiatrists, 2008
- A trial to decrease the prevalence of depression in Australian Nursing Homes
Depression is common among residents of aged care facilities, although symptoms are often not detected or treated.
The Professional Education to Aged Care (PEAC) was designed to enhance knowledge about depression and anxiety in residential care. PEAC was developed as an e-learning program for the elderly and their carers to assist in detecting and managing anxiety and depression.
Through a trial of the PEAC platform, we will test whether the addition of a behavioural activation component is more efficacious than the PEAC alone, in terms of reducing the frequency of depressive symptoms among nursing home residents.
- Depression in Dementia
This study will look at what contributes to depression and other behavioural symptoms in people with Alzheimer's-type dementia.
These symptoms are common and difficult to treat so it is important we gain a better understanding of why they develop and look at ways to prevent their occurrence.
The study will also test a simple, safe and novel intervention aimed at altering the biases we have in our thought processes that may underlie the development of these symptoms.
- An Australasian trial of the efficacy of fluoxetine in improving functional recovery after acute stroke
Treatments that improve recovery after stroke are lacking, even though stroke is one of the top three causes of disability.
This project came about after reviewing world literature and finding a number of very small studies that suggest antidepressant drug, fluoxetine, may improve the recovery in stroke patients.
The AFFINITY trial was born, where we are testing the drug among 1600 Australians and New Zealanders who have had a stroke. The trial aims to find out whether taking fluoxetine for six months after a stroke improves recovery compared to a placebo.